New Perspectives in Medical Oncology : Molecular Medicine and its Perspectives
PDF

Keywords

Medical Oncology
Molecular Medicine
Perspectives

Categories

How to Cite

1.
Blay J-Y, Tredan O, Perol D. New Perspectives in Medical Oncology : Molecular Medicine and its Perspectives. Integr J Med Sci [Internet]. 2017 May 3 [cited 2022 Jun. 30];4:60-4. Available from: https://www.mbmj.org/index.php/ijms/article/view/59

Abstract

The molecular medicine of cancer is based on the identification of genomic abnormalities in the DNA of tumor cells, guiding the treatment of patients, by choosing inhibitors acting on the mutated proteins encoded by the mutated genes. However, for the last 10 years, there has been a very rapid emergence of a new corpus of knowledge describing the genomic abnormalities of cancer cells in international programs such as ICGC or TCGA, leading to new nosological classifications, but also showing the extreme complexity and clonal variability of cancer cells in the human patient. The optimal use of this body of new data effectively. This requires 1) the construction of diagnostic platforms progressively exploring with greater depth the molecular anomalies of each individual patient and 2) the organization of multidisciplinary molecular consultation meetings to integrate these data into the clinical and global context of the patient. This evolution will also require a growing
contribution of bio-informatics. This short article provides a short update on the evolution of this molecular medicine of cancer.

https://doi.org/10.15342/ijms.v4is.143
PDF

References

International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker DA, Bell C, Bernabé RR, Et al. International network of cancer genome projects. Nature. 2010; 464(7291):993-8. https://doi.org/10.1038/nature08987

Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 Oct 23;455(7216):1061-8. https://doi.org/10.1038/nature07385

Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 2;488(7409):100-5. https://doi.org/10.1038/nature11284

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333-9. https://doi.org/10.1038/nature12634

Gundem G, Van Loo P, Kremeyer B, Alexandrov BL, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015 Apr 16; 520(7547):353-7. https://doi.org/10.1038/nature14347

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016 Jun 2;534(7605): 47-54. https://doi.org/10.1038/nature17676

Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013 Nov 7; 155(4): 948-62. https://doi.org/10.1016/j.cell.2013.10.011

Hyman DM, Puzanov I, Subbiah V, Faris EJ, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20; 373(8):726-36. https://doi.org/10.1056/nejmoa1502309

Bang YJ, Van Cutsem E, Feyereislova A, Chung CH, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28; 376(9742):687-97. https://doi.org/10.1016/s0140-6736(10)61121-x

McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015 Jan 12; 27(1):15-26. https://doi.org/10.1016/j.ccell.2014.12.001

Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013 Nov;31(11):1023-31. https://doi.org/10.1038/nbt.2696

Van Allen EM, Wagle N, Stojanov P, Perrin LD, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8. https://doi.org/10.1038/nm.3559

Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl SA, Davis C, et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016 Jun 1; 8(1):62. https://doi.org/10.1186/s13073-016-0313-0

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012 Nov; 13 (11):1133-40. https://doi.org/10.1016/s1470-2045(12)70474-6

Dickson MA, Schwartz GK, Keohan ML, D’angelo PS, Gounder MM, ChiP, et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Jul 1; 2(7):937-40. https://doi.org/10.1001/jamaoncol.2016.0264

Seront E, Rottey S, Sautois B, Kerger J, D’hondt AL, Verschaeve, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012 Oct;23(10):2663-70. https://doi.org/10.1093/annonc/mds057

Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Target Oncol. 2013 Dec; 8(4):243-51.https://doi.org/10.1007/s11523-012-0242-9

Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Jun; 17(6):811-821. https://doi.org/10.1016/s1470-2045(16)00106-6

André F, Bachelot T, Commo F, Campone M, Aenedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014; 15:267-74. https://doi.org/10.1016/s1470-2045(13)70611-9

Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch MD, Borad JM, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010 Nov 20; 28:4877-83. https://doi.org/10.1200/jco.2009.26.5983

Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich MS, Baggerly K, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110. https://doi.org/10.18632/oncotarget.4040

Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016 Jul 1; 76(13):3690-701. https://doi.org/10.1158/0008-5472.can-15-3043

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop WG, et al. Prospective clinical study of precision oncology in solid tumors. J Natl Cancer Inst. 2015 Nov 9; 108(3): djv332. https://doi.org/10.1093/jnci/djv332

Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, et al. Circulating Cell -Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clin Cancer Res. 2016 Jun 15; 22(12):2960-8. https://doi.org/10.1158/1078-0432.ccr-15-2470

Massard C. Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 trial. Ann Oncol 2015 Mar; 26(2):ii3. https://doi.org/10.1093/annonc/mdv081.7

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015 Oct;16(13):1324-34. https://doi.org/10.1016/s1470-2045(15)00188-6

Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J Natl Cancer Inst. 2015 Nov; 108(4)::djv362. https://doi.org/10.1093/jnci/djv362

Hainsworth JD, Meric-Bernstam F, Swanton C, Swanton C, Hurwitz H, Spiqel RD, et al. Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway, an open-label, phase IIa umbrella basket study. J Clin Oncol. 2018 Feb 20:36 (6): 536-542. https://doi.org/10.1200/jco.2017.75.3780

Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017 Jan 20; 355 (6322): eaaf8399. https://doi.org/10.1126/science.aaf8399

Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, et al. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol. 2016 Aug; 27(8):1443-8. https://doi.org/10.1093/annonc/mdw192

Siu LL, Lawler M, Haussler D, Knoppers MB, Lewin J, Vis JD, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016 May 5;22(5):464-71. https://doi.org/10.1038/nm.4089

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2017 Jean-Yves Blay et al.

Downloads

Download data is not yet available.